Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glycorex Transplantation ABFRA:O33 -31.05%61 Days Payable is 47.21 as of Mar. 2026, which is 71% below its 10-year median of 160.25. GuruFocus rates FRA:O33 with a GF Score™ of 61/100 and a GF Value™ of €0.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, Glycorex Transplantation AB ranks worse than 63.35% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O33 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's Days Payable falls into.
Glycorex Transplantation AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB (FRA:O33) has a Days Payable of 47.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Glycorex Transplantation AB and its competitors. This is 71% below median its historical median of 160.25. Over the past decade, Glycorex Transplantation AB's Days Payable has ranged from 59.52 to 784.94. According to the industry distribution chart, Glycorex Transplantation AB ranks #446 out of 704 companies in the Biotechnology industry, placing it in the top 63.4%.
Is Glycorex Transplantation AB's Days Payable too high?
Glycorex Transplantation AB's current Days Payable of 47.21 is 71% below median its 10-year median of 160.25. Over the past 10 years, this metric has ranged from a low of 59.52 to a high of 784.94. The Biotechnology industry median Days Payable is 112.83. Glycorex Transplantation AB's value of 47.21 is 58.2% below this industry median. Based on the distribution chart, Glycorex Transplantation AB ranks #446 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #446 out of 704 companies for Days Payable. This places Glycorex Transplantation AB in the lower half of its industry. The industry median Days Payable is 112.83. Glycorex Transplantation AB's value of 47.21 is 58.2% below this benchmark. Historically, Glycorex Transplantation AB's own Days Payable has ranged from 59.52 to 784.94 over the past decade. While the company's 10-year median is 160.25 vs. the industry median of 112.83, Glycorex Transplantation AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glycorex Transplantation AB's current Days Payable of 47.21 is 58.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Glycorex Transplantation AB and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glycorex Transplantation AB's current Days Payable is 47.21, which is 71% below median its own 10-year median of 160.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current Days Payable is 47.21, which is 71% below median its 10-year median of 160.25 and 58.2% below the Biotechnology industry median of 112.83. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current Days Payable is 47.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14.
GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.
Key valuation signals for FRA:O33:
Days Payable: 47.21 (71% below median its 10-year median of 160.25)
GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
Industry Position: 58.2% below the Biotechnology median (#446 of 704)
No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for FRA:O33
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O33 has been successfully added to your 
